# Request for Approval under the "Generic Clearance for the Collection of Routine Customer Feedback" (OMB Control Number: 0925-0668)

### TITLE OF INFORMATION COLLECTION:

Grantees' Perceptions Regarding the NIAID DAIDS Phased Innovation Award (R21/R33) Funding Mechanism

#### **PURPOSE:**

The Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) has utilized the biphasic R21/R33 grant mechanism to support AIDS Vaccine Research and the Microbicide Innovation Program. NIAID DAIDS is interested in knowing grantees' overall satisfaction with the Phased Innovation Award R21/R33 grant funding mechanism. It is also of interest to obtain information regarding key aspects of the funding mechanism that were particularly helpful or challenging. This survey is part of a customer satisfaction assessment to examine the NIAID DAIDS Phased Innovation Award Program implementation and grantees' perceptions to date.

#### **DESCRIPTION OF RESPONDENTS:**

**TYPE OF COLLECTION:** (Check one)

Potential survey respondents are the Principal Investigators (PIs) who received NIAID DAIDS AIDS Vaccine Research (AVR) or Microbicide Innovation Program (MIP) phased innovation awards from FY 2006 through FY 2012. A total of 76 applicants received an award under this R21/R33 funding mechanism.

[ ] Customer Comment Card/Complaint Form	[X] Customer Satisfaction Survey
[ ] Usability Testing (e.g., Website or Software)	[ ] Small Discussion Group
[] Focus Group	[ ] Other:

### **CERTIFICATION:**

I certify the following to be true:

- 1. The collection is voluntary.
- 2. The collection is low-burden for respondents and low-cost for the Federal Government.
- 3. The collection is non-controversial and does <u>not</u> raise issues of concern to other federal agencies.
- 4. The results are <u>not</u> intended to be disseminated to the public.
- 5. Information gathered will not be used for the purpose of <u>substantially</u> informing <u>influential</u> policy decisions.
- 6. The collection is targeted to the solicitation of opinions from respondents who have experience with the program or may have experience with the program in the future.

Name: Madelon Halula, PhD DHHS, NIH, NIAID, DAIDS

To assist review, please provide answers to the following question:

_ ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
<ol> <li>Is personally identifiable information:</li> <li>Is personally identifiable information (PII) collected</li> <li>If Yes, will any information that is collected be inclearly actional privacy Act of 1974? [ ] Yes [ ] No</li> <li>If Yes, has an up-to-date System of Records Notice</li> </ol>	luded in records	that are subject to	
<b>Gifts or Payments:</b> Is an incentive (e.g., money or reimbursement of expendanticipants? [ ] Yes [ <b>X</b> ] No	nses, token of ap	preciation) provid	ded to
BURDEN HOURS			
Category of Respondent	No. of Respondents	Participation Time	Burden
Private Sector (Academia)	76	15 minutes	19.00 h
Totals	76	15 minutes	19.00 h
FEDERAL COST: The estimated annual cost to the I  If you are conducting a focus group, survey, or plan provide answers to the following questions:	J		
<ol> <li>The selection of your targeted respondents</li> <li>Do you have a customer list or something similar the respondents and do you have a sampling plan for selection.</li> </ol>	electing from thi	-	
If the answer is yes, please provide a description of bot the answer is no, please provide a description of how y respondents and how you will select them?	,	1 0 1	•
The universe of potential respondents is the Principal In Vaccine Research or Microbicide Innovations Program through FY 2012. We intend to invite all 76 PIs to conresponse rate, giving us 68 PIs who actually complete to	phased innovat	ion awards from	FY 2006

## **Administration of the Instrument**

1.	How will you collect the information? (Check all that apply)
	[X] Web-based or other forms of Social Media
	[ ] Telephone
	[ ] In-person
	[ ] Mail
	[ ] Other, Explain
2.	Will interviewers or facilitators be used? [ ] Yes [ <b>X</b> ] No